Renibus Therapeutics

What Renibus Therapeutics does

Renibus Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Southlake, Texas, focused on developing therapeutics for cardio, renal, and metabolic diseases. The company operates two lead Phase 3 assets: RBT-1 (stannic protoporfin/iron sucrose), a first-in-class pharmacologic preconditioning agent administered as a single intravenous dose 24-48 hours prior to cardiac surgery to reduce post-operative complications via induction of antioxidant (Nrf2), anti-inflammatory (IL-10), and iron-scavenging (ferritin/hepcidin) pathways; and Veverimer, an oral non-absorbed polymer that binds hydrochloric acid in the gastrointestinal tract to increase serum bicarbonate in chronic kidney disease patients with metabolic acidosis. Three additional pipeline assets (RBT-2, RBT-3, RBT-9) are at earlier stages targeting CKD progression, iron/nephrotoxicity, and antiviral indications, respectively.

The lead RBT-1 program completed its 423-patient Phase 3 PROTECT trial across 40 sites in the US and Canada in April 2026; the trial did not meet its primary endpoint in the overall population, though post-hoc analyses suggest potential benefit in higher-risk patient subgroups. Veverimer received FDA Orphan Drug Designation in 2025 for anti-glomerular basement membrane disease and is expected to enter a 150-participant Phase 3 REVIVE trial in early 2026 for the broader CKD-metabolic acidosis indication. The company has secured FDA Breakthrough Therapy and Fast Track designations for RBT-1 and composition-of-matter patents across multiple jurisdictions.

As a pre-revenue clinical-stage company, Renibus has no products on market and relies on capital markets for funding; cumulative disclosed funding exceeds $138 million across rounds from 2016 through 2023, including a $33 million bridge financing in November 2022 (with Oxford Finance LLC as lead debt provider) and an upsized $72 million Series B in 2023. The future commercial model would involve hospital-administered specialty distribution for RBT-1 and retail/specialty pharmacy channels for Veverimer, supported by an enterprise field sales motion targeting cardiac surgeons, anesthesiologists, and nephrologists through medical conference engagement and key opinion leader relationships.

Name

Renibus Therapeutics

Legal name

Renibus Therapeutics, Inc.

Website

https://renibus.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Clinical-stage biopharmaceutical company developing therapies for cardio, renal, and metabolic diseases, with two Phase 3 assets: RBT-1 for reducing post-operative cardiac surgery complications and Veverimer for metabolic acidosis in chronic kidney disease.

Ownership category

akta.pro rank

Product category

Cardiometabolic Therapeutics

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Rare Renal & Nephrology Disorder Therapies (HLAIAIAI), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Clinical-stage biopharmaceutical
• Pharmacologic preconditioning therapy
• Cardiorenal disease therapeutics
• Metabolic acidosis treatment
• Post-operative complication prevention

Headquarters

HQ city

Southlake

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical product sales (future): Renibus is a pre-revenue clinical-stage biopharmaceutical company. The company is developing two Phase 3 clinical assets: RBT-1 for reducing post-operative complications in cardiac surgery, and Veverimer for metabolic acidosis in chronic kidney disease. If approved, the company would generate revenue through pharmaceutical product sales, likely as a specialty drug administered in hospital settings (RBT-1) and chronic outpatient therapy (Veverimer).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Renibus Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for cardio, renal, and metabolic diseases. Its lead candidates include RBT-1, a single-dose intravenous pharmacologic preconditioning agent administered prior to cardiac surgery to reduce post-operative complications, and Veverimer, an oral, non-absorbed polymer that binds hydrochloric acid in the GI tract to treat metabolic acidosis in chronic kidney disease patients. The company also has three earlier-stage pipeline assets (RBT-2, RBT-3, RBT-9) targeting antifibrotic, iron-repletion, and antiviral indications.

Product overview

Renibus Therapeutics is a clinical-stage biopharmaceutical company with two Phase 3 clinical assets: RBT-1 and Veverimer. RBT-1 is a novel pharmacologic preconditioning agent (stannic protoporfin/iron sucrose) designed to reduce post-operative complications in cardiac surgery patients. Veverimer is an oral non-absorbed hydrochloric acid binder for treating metabolic acidosis in chronic kidney disease patients. The company also has three earlier-stage pipeline assets: RBT-2 (tetrahydrocurcumin, antioxidant/antifibrotic for CKD), RBT-3 (iron nanoparticle for nephrotoxicity), and RBT-9 (antiviral/anti-inflammatory agent). The company focuses on cardio, renal, and metabolic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• RBT-1 (stannic protoporfin / iron sucrose) A first-in-class pharmacologic preconditioning agent administered as a single intravenous dose 24–48 hours prior to cardiac surgery. The fixed-dose combination of stannic protoporfin and iron sucrose induces antioxidant (Nrf2), anti-inflammatory (IL-10), and iron-scavenging (ferritin, hepcidin) pathways to protect multiple organs from surgical injury. Intended to reduce post-operative complications in CABG and valve surgery patients on cardiopulmonary bypass.
• Veverimer An oral, non-absorbed polymer that binds hydrochloric acid in the gastrointestinal tract. Designed to increase serum bicarbonate concentrations in adults with chronic kidney disease and metabolic acidosis without adding sodium or potassium. Acquired from Tricida and being developed by Renibus for CKD-metabolic acidosis (Phase 3 REVIVE) and anti-GBM disease.
• RBT-2 (tetrahydrocurcumin) Oral antioxidant and antifibrotic drug candidate targeting delayed chronic kidney disease progression. In IND-enabling preclinical studies.
• RBT-3 (iron sucrose) A novel, low molecular weight iron nanoparticle with potential to rapidly restore iron levels and improve blood product utilization in cardiac surgery and/or ER patients. Demonstrated potential to mitigate cisplatin-induced nephrotoxicity in preclinical models.
• RBT-9 (stannic protoporfin) A potent anti-inflammatory and antioxidant drug candidate with broad-spectrum antiviral properties. Previously evaluated in a 42-patient Phase 2 randomized placebo-controlled trial in high-risk COVID-19 patients.

Quantifiable outcome

• Statistically significant -2.7 days reduction in ICU days (p=0.0243)
• +8 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor.

• FHCC (Florida Hospital Cancer Institute)minorOthersFHCC is listed as an advocacy research partner on the Renibus Patients page, alongside UCI, NIH, University of Arizona, and ERAS Society, suggesting collaborative relationships for clinical research and patient advocacy.
• University of California, Irvine (UCI)minorOthersUCI is listed as an advocacy research partner and is home to scientific advisors including Alpesh Amin, MD, who serves as Chair of Department of Medicine. Multiple key opinion leaders from UCI are involved in Renibus clinical programs.
• National Institutes of Health (NIH)minorOthersNIH is listed as an advocacy research partner on the Renibus Patients page, indicating collaborative relationship in clinical research and potential funding support.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Tricida: Original developer of veverimer for metabolic acidosis in CKD. Renibus acquired the asset after Tricida received an FDA Complete Response Letter and subsequently wound down. Most directly comparable company in terms of the lead asset's prior clinical history.
• Akebia Therapeutics: Clinical-stage nephrology-focused biopharma developing vadadustat (HIF-PHI for anemia in CKD). Direct peer in the late-stage kidney disease specialty pharma space with similar regulatory and capital-raising dynamics.
• Ardelyx: Nephrology-focused biotech that developed tenapanor (Xphozah) for hyperphosphatemia in CKD and IBSRELA for IBS-C. Closely comparable specialty kidney disease developer with a similar commercial-stage trajectory.
• ProKidney: Late-stage biotech developing cell therapy (rilparencel) for CKD. Direct peer in the kidney disease specialty pharma space targeting disease progression in similar patient populations.
• Unicycive Therapeutics: Clinical-stage biotech focused on kidney disease with lead asset oxylanthanum carbonate (Renazorb) for hyperphosphatemia in CKD. Closely comparable specialty renal developer in similar pre-commercial stage.
• Tenax Therapeutics: Clinical-stage biotech developing levosimendan for cardiac surgery and PH-HFpEF. Directly comparable in the cardiac surgery specialty pharma space targeting peri-operative outcomes.
• Spectral Medical: Clinical-stage company developing endotoxin removal (PMX) for cardiac surgery and septic shock. Comparable specialty player focused on reducing post-operative complications in cardiac surgery patients.
• Corvidia Therapeutics: Was a clinical-stage cardio-renal-metabolic biotech developing ziltivekimab, acquired by Novo Nordisk in 2020 for up to $2.1B. Closely aligned specialty cardio-renal biotech with similar therapeutic positioning and exit pathway.

Broad incumbents

• AstraZeneca: Acquired ZS Pharma (Lokelma) for $2.7B and now operates a major nephrology franchise including Farxiga for CKD. Broad incumbent with overlapping kidney disease strategic interest and prior M&A precedent in this exact space.
• Vifor Pharma (CSL Vifor): Established nephrology/iron deficiency franchise (acquired by CSL in 2022). Broad incumbent operating across the same cardio-renal specialty channels with overlapping hospital and nephrology customer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/renibusinc
• LinkedInlinkedin.com/company/renibus-therapeutics-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renibus Therapeutics